undamentalytics Newsletter
Sign in

Atyr Pharma Inc (ATYR) stock

Add to watchlist

Add holding +

NASDAQ: ATYR Nasdaq Biotechnology Next results ~November 5, 2026

Atyr Pharma Inc is a US-listed company in the biotechnology industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: data-quality checks not passed.

Price vs value

Under review: data-quality checks not passed. We'll show the comparison once resolved.

Atyr Pharma Inc valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders1 buying, 3 selling1 purchase and 3 sales by directors and officers, last 12 monthsInsider trades
  • Funds45 adding, 66 cuttingOf 17 active managers that changed their stake, 9 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Atyr Pharma files

Where Atyr Pharma stands after its latest 10-Q

Atyr Pharma has little or no product revenue yet; it used $55m of cash in the twelve months to June 2026. The diluted share count is up 16.8% on a year earlier, which dilutes existing holders. It passes 1 of our 1 financial-health checks.

Our model value for Atyr Pharma is under review, so past values are not shown until it is resolved.

Source: 10-Q filed August 7, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 5, 2026 (estimated)

Atyr Pharma Inc's trailing-twelve-month revenue fell 19.1% year on year, with a free-cash-flow margin of -32664.7%.

Current signal Operating margin compressing: TTM operating margin fell to -40856.3%, down 11956.7pp year over year.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Net cash. Cash exceeds long-term debt by $0.0bn.

Things to watch

  • Revenue shrinking. Revenue fell 19.1% over the last 12 months.
  • Loss-making. Operating margin is -40856.3%: costs exceed revenue.
  • Margins narrowing. Operating margin is down 11956.7 points on a year ago.
  • Burning cash. Free cash flow was -32664.7% of revenue over the last 12 months.
  • Heavy stock-based pay. Stock pay equals 2630.0% of revenue: a real cost that cash-flow figures leave out.
  • Share dilution. Diluted shares rose 16.8% in a year.

Latest results: FY2025 Q4

Filed March 5, 2026
Earnings per share
-$4.40 against an average estimate of -$5.00: beat by 12.0%
Guidance given
reduction in annualized operating expenses $13m (fourth quarter of 2026)
Next report
November 5, 2026; average EPS estimate -$4.00

Atyr Pharma's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+27.3%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$190,000
Operating margin
-40856.3%
Net margin
-39009.5%
EPS (TTM, diluted)
$-0.62

Growth

Revenue growth
−19.1%
Change in growth rate
+0.0 pts
Share count change
+16.8%

Cash

Free cash flow (TTM)
-$54.8M
FCF margin
-32664.7%
Stock pay % of revenue
2630.0%

Earnings

Last results
August 7, 2026

News & updates

Updated November 2, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Our research
  2. Governance
  3. Shareholder vote
  4. Announcement
  5. Results
  6. Guidance
  7. Agreement ended

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Atyr Pharma Inc valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: data-quality checks not passed.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 5, 2026, after the close. Analysts expect revenue of $0 and EPS of −$4.00 (range −$4.80 to −$3.20) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$16.46 +49% — −100%
Next −$17.75 −8% — 0%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −21.4% on 90 days ago. In the last 30 days, 4 analysts raised Atyr Pharma Inc's forecast and 0 cut it.

Consensus EPS forecast Atyr Pharma Inc, last 90 days
−$30.00 −$20.00 −$10.00 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$20.93 Current fiscal year, 60 days ago: −$22.55 Current fiscal year, 30 days ago: −$16.30 Current fiscal year, 7 days ago: −$16.46 Current fiscal year, Now: −$16.46 −$16.46 Next fiscal year, 90 days ago: −$23.30 Next fiscal year, 60 days ago: −$24.49 Next fiscal year, 30 days ago: −$17.69 Next fiscal year, 7 days ago: −$17.75 Next fiscal year, Now: −$17.75 −$17.75

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$20.93−$23.30
60 days ago −$22.55−$24.49
30 days ago −$16.30−$17.69
7 days ago −$16.46−$17.75
Now −$16.46−$17.75

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$5.00 −$4.40 +12.0%
Mar 2026 −$5.50 −$4.40 +20.0%
Dec 2025 −$7.00 −$5.60 +20.0%
Sept 2025 −$7.38 −$10.40 −40.9%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, August 7, 2026
  • reduction in annualized operating expenses fourth quarter of 2026 about $13m
    “The Company expects that this restructuring and additional cost saving measures will reduce annualized operating expenses by approximately $13 million, beginning in the fourth quarter of 2026.” source

Figures and quotations are management's, copied from the company's own press release (SEC 8-K exhibit) and checked word for word against it. Forward-looking statements are the company's expectations, not ours and not advice; guidance can change or be missed.

Analyst recommendations

9 analysts, Oct 2026
Buy444%
Hold556%
Sell00%

Monthly trend

  1. Oct 20262259
  2. Sep 20262259
  3. Aug 20262259

Counts of recommendations published by analysts covering Atyr Pharma Inc, by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
10.5%
of tradable shares
Days to cover
1.33
at average volume
Short interest, 1 month
−4%
to October 15, 2026
Held by institutions
—
of shares
Held by insiders
—
of shares
Employees
58
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Recent prices are available. Older price history and the statistics that need it are being loaded in the background.

Price behaviour

52-week range
Not enough history
From 52-week high
—
vs 50-day average
—
vs 200-day average
—
Volatility (1 year)
—
Beta vs S&P 500
—

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Fundamentals

Revenue (TTM) Atyr Pharma Inc
$0 $5M $10M $15M FY20 Q4 FY23 Q4 FY24 Q3 FY25 Q4 Revenue (TTM), FY20 Q4: $10.5M Revenue (TTM), FY23 Q2: $10.4M Revenue (TTM), FY23 Q3: $10.7M Revenue (TTM), FY23 Q4: $353K Revenue (TTM), FY24 Q1: $588K Revenue (TTM), FY24 Q2: $588K Revenue (TTM), FY24 Q3: $235K Revenue (TTM), FY24 Q4: $235K Revenue (TTM), FY25 Q1: $0 Revenue (TTM), FY25 Q2: $0 Revenue (TTM), FY25 Q3: $190K Revenue (TTM), FY25 Q4: $190K $190K

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period Revenue (TTM)
FY20 Q4 $10.5M
FY23 Q2 $10.4M
FY23 Q3 $10.7M
FY23 Q4 $353K
FY24 Q1 $588K
FY24 Q2 $588K
FY24 Q3 $235K
FY24 Q4 $235K
FY25 Q1 $0
FY25 Q2 $0
FY25 Q3 $190K
FY25 Q4 $190K
Revenue growth, TTM YoY Atyr Pharma Inc
-100% -50% 0% FY24 Q2 FY24 Q4 FY25 Q2 FY25 Q4 Revenue growth, TTM YoY, FY24 Q2: -94.3% Revenue growth, TTM YoY, FY24 Q3: -97.8% Revenue growth, TTM YoY, FY24 Q4: -33.4% Revenue growth, TTM YoY, FY25 Q1: -100.0% Revenue growth, TTM YoY, FY25 Q2: -100.0% Revenue growth, TTM YoY, FY25 Q3: -19.1% Revenue growth, TTM YoY, FY25 Q4: -19.1% -19.1%

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period Revenue growth, TTM YoY
FY24 Q2 -94.3%
FY24 Q3 -97.8%
FY24 Q4 -33.4%
FY25 Q1 -100.0%
FY25 Q2 -100.0%
FY25 Q3 -19.1%
FY25 Q4 -19.1%
Operating margin (TTM) Atyr Pharma Inc
-60000% -40000% -20000% 0% FY20 Q2 FY23 Q2 FY24 Q1 FY25 Q4 Operating margin (TTM), FY20 Q2: -185.5% Operating margin (TTM), FY20 Q3: -198.1% Operating margin (TTM), FY20 Q4: -152.2% Operating margin (TTM), FY23 Q2: -460.1% Operating margin (TTM), FY23 Q3: -436.8% Operating margin (TTM), FY23 Q4: -15557.8% Operating margin (TTM), FY24 Q1: -9994.6% Operating margin (TTM), FY24 Q2: -10633.5% Operating margin (TTM), FY24 Q3: -28958.7% Operating margin (TTM), FY24 Q4: -28899.6% Operating margin (TTM), FY25 Q3: -41395.3% Operating margin (TTM), FY25 Q4: -40856.3% -40856.3%

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period Operating margin (TTM)
FY20 Q2 -185.5%
FY20 Q3 -198.1%
FY20 Q4 -152.2%
FY23 Q2 -460.1%
FY23 Q3 -436.8%
FY23 Q4 -15557.8%
FY24 Q1 -9994.6%
FY24 Q2 -10633.5%
FY24 Q3 -28958.7%
FY24 Q4 -28899.6%
FY25 Q3 -41395.3%
FY25 Q4 -40856.3%
FCF margin (TTM) Atyr Pharma Inc
-40000% -30000% -20000% -10000% 0% FY20 Q2 FY23 Q2 FY24 Q1 FY25 Q4 FCF margin (TTM), FY20 Q2: -160.4% FCF margin (TTM), FY20 Q3: -176.2% FCF margin (TTM), FY20 Q4: -148.3% FCF margin (TTM), FY23 Q2: -389.3% FCF margin (TTM), FY23 Q3: -352.4% FCF margin (TTM), FY23 Q4: -10605.1% FCF margin (TTM), FY24 Q1: -9863.4% FCF margin (TTM), FY24 Q2: -10892.7% FCF margin (TTM), FY24 Q3: -28555.7% FCF margin (TTM), FY24 Q4: -29440.0% FCF margin (TTM), FY25 Q3: -33154.2% FCF margin (TTM), FY25 Q4: -32664.7% -32664.7%

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period FCF margin (TTM)
FY20 Q2 -160.4%
FY20 Q3 -176.2%
FY20 Q4 -148.3%
FY23 Q2 -389.3%
FY23 Q3 -352.4%
FY23 Q4 -10605.1%
FY24 Q1 -9863.4%
FY24 Q2 -10892.7%
FY24 Q3 -28555.7%
FY24 Q4 -29440.0%
FY25 Q3 -33154.2%
FY25 Q4 -32664.7%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025
Income
Revenue 0 10 0 10 0 0 0
EBITDA −22 −15 −34 −46 −54 −67 −77
Operating income −23 −16 −34 −46 −55 −68 −78
Net income −16 −16 −34 −45 −50 −64 −74
Diluted EPS −$1.76 −$0.44 −$0.89 −$0.80 −$0.94 −$0.86 −$0.80
Growth (year on year)
Revenue — +>999% −100.0% — −96.6% −33.4% −19.1%
Margins
EBITDA margin <−999% −146.7% — −444.6% <−999% <−999% <−999%
Operating margin <−999% −152.2% — −446.8% <−999% <−999% <−999%
Net margin <−999% −155.2% — −436.5% <−999% <−999% <−999%
Free-cash-flow margin <−999% −148.3% — −419.1% <−999% <−999% <−999%
Cash flow
Cash from operations −20 −15 −33 −42 −33 −69 −62
Capital spending 0 0 0 2 4 0 0
Free cash flow −20 −16 −33 −44 −37 −69 −62
Stock-based pay 2 1 2 2 3 3 5
Free cash flow after stock pay −22 −17 −35 −46 −40 −72 −67
Balance sheet
Cash 9 17 2 10 23 11 11
Total debt 11 0 0 0 0 0 0
Net debt (negative = net cash) 2 −17 −2 −10 −23 −11 −11
Diluted shares 13m 37m 38m 57m 54m 74m 93m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

1 of 1 checks passed · June 30, 2026
What it owns · $70m
Short-term assets $58mLonger-term assets $11m
What it owes, and who funded it · $60m
Short-term liabilities $11mShareholders' equity $49m
  • Short-term assets cover short-term liabilities $58m of assets due within a year against $11m of liabilities due within a year.
  • Short-term assets cover long-term liabilities Not assessable from the reported split. Not assessable.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Atyr Pharma Inc's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+16.8%
year over year
R&D spending
31694.2%
of revenue

Competitors: side by side with peers

Closest by revenue in biotechnology
Last 12 months unless stated ATYR CLNN CLDX CRVO IBIO LSTA Median
Revenue, last 12 months $190000 $197000 $158000 $331295 $100000 $100000 $55m
Revenue growth, last 12 months −19.1% −31.1% −97.3% −95.7% −75.0% −90.7% 12.2%
Revenue growth, 3-year average −71.9% −36.9% −63.5% −52.7% −62.4% — 13.1%
Revenue growth, latest quarter −100.0% 233.3% −97.0% −100.0% −100.0% −100.0% 10.2%
Gross margin — 70.1% — 100.0% 59.9% 7.7% 82.9%
Operating margin <−999% <−999% <−999% <−999% <−999% <−999% −191.1%
Operating margin, 3-year average <−999% <−999% <−999% <−999% <−999% <−999% −365.3%
Net margin <−999% <−999% <−999% <−999% <−999% <−999% −172.8%
Cash from operations / revenue <−999% <−999% <−999% <−999% <−999% <−999% −168.8%
Free-cash-flow margin <−999% <−999% <−999% — <−999% <−999% −168.1%
Free-cash-flow margin, 3-year average <−999% <−999% <−999% — <−999% <−999% −313.4%
Stock pay / revenue >999% >999% >999% 393.0% >999% >999% 20.7%
Change in share count 16.8% 35.4% 4.7% 8.4% 13.9% 5.1% 8.3%

Median of all 185 companies we cover in biotechnology. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Who owns it

Funds buying and selling
Reported value
$24.2M
Institutions reporting
89
Shares held vs prior quarter
▼ 27.5%
Positions opened / closed
16 / 36

Top buyers and sellers, Q2 2026: 45 institutions bought and 66 sold ; the biggest buyer was Kalehua Capital Management LLC (+3.6M shares) and the biggest seller FMR LLC (−12.2M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Federated Hermes, Inc. $5.1M 8.5M 20.9% ▼ 19.0%
Vanguard Capital Management LLC $2.3M 3.8M 9.4% ▼ 0.1%
Kalehua Capital Management LLC $2.1M 3.6M 8.8% New
Gsa Capital Partners LLP $2.1M 3.5M 8.5% ▲ 105.1%
AQR Capital Management LLC $1.6M 2.6M 6.4% ▲ 426.3%
FMR LLC $1.5M 2.5M 6.1% ▼ 83.2%
Blackrock, Inc. $1.1M 1.8M 4.5% ▼ 71.6%
Jane Street Group, LLC $1M 1.7M 4.2% ▲ 3448.9%
UBS Group AG $914,097 1.5M 3.8% ▼ 60.4%
Morgan Stanley $801,882 1.3M 3.3% ▲ 9.6%
Two Sigma Investments, LP $743,104 1.2M 3.1% ▲ 8.8%
Citadel Advisors LLC $741,265 1.2M 3.1% ▲ 2521.9%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Atyr Pharma Inc's complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $50,000 1 trade by 1 insider, last 12 months Insider sales History → $6,293 3 trades by 3 insiders · 0% under pre-set plans
Net ▲ $43,707 net buying
Insider Date Trade Shares Price Value
Schimmel Paul Director May 27, 2026 Buy 100,000 $0.50 $50,000
Denyes Nancy General Counsel February 4, 2026 Sell 1,118 $0.98 $1,096
Broadfoot Jill Marie Chief Financial Officer February 4, 2026 Sell 1,558 $0.98 $1,527
Shukla Sanjay President and CEO February 4, 2026 Sell 3,745 $0.98 $3,670

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 2, 2026 estimated from the company's past filing pattern, not announced

  • August 7, 2026
  • May 15, 2026
  • May 11, 2026
  • March 5, 2026
  • November 6, 2025
  • May 7, 2025

Recent SEC filings

Data status

When each part of this page on Atyr Pharma Inc was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Atyr Pharma Inc in brief

What does Atyr Pharma Inc do?
Atyr Pharma Inc is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Atyr Pharma Inc's stock ticker?
Atyr Pharma Inc trades under the ticker ATYR on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Atyr Pharma Inc's revenue, and how fast is it growing?
Over its most recent trailing twelve months, Atyr Pharma Inc reported revenue of $190,000, 19.1% lower than a year earlier, according to its SEC filings.
What is Atyr Pharma Inc's free cash flow?
Atyr Pharma Inc's free-cash-flow margin is -32664.7% of revenue over the trailing twelve months.
Who are Atyr Pharma Inc's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Federated Hermes, Inc., Vanguard Capital Management LLC and Kalehua Capital Management LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Who are Atyr Pharma Inc's competitors?
In our Biotechnology peer group, the companies closest to Atyr Pharma Inc are Clene Inc., Celldex Therapeutics, Inc., Cervomed Inc., Ibio, Inc. and Lisata Therapeutics, Inc. The side-by-side comparison below sets their revenue, margins and growth against Atyr Pharma Inc's.
Are insiders buying or selling Atyr Pharma Inc stock?
Over the last 12 months, Atyr Pharma Inc's directors and officers reported 1 open-market purchases and 3 sales on Form 4. The insider trading page charts every trade.
When is Atyr Pharma Inc's next earnings date?
Around November 5, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Atyr Pharma Inc announces its own schedule.